Abstract:
:Systemic therapy for advanced non-small cell lung cancer (NSCLC) has evolved over the last two decades, with modest improvements in quality of life and overall survival. A plateau has been reached with traditional chemotherapy, and efforts are now being directed at developing molecularly targeted agents. To date, three such agents have been found to improve overall survival in advanced NSCLC. Erlotinib, a small-molecule inhibitor of the epidermal growth factor receptor, was approved by the US FDA in 2004 as second- or third-line treatment for advanced NSCLC. Bevacizumab, an antibody to vascular endothelial growth factor, a key mediator of angiogenesis, received approval in 2006, after a randomized trial reported a median survival of 1 year when bevacizumab was added to first-line chemotherapy. More recently, cetuximab, an antibody to the epidermal growth factor receptor, was found to improve outcome when added to chemotherapy, and FDA approval is anticipated. Several additional agents are currently being evaluated in randomized trials, with encouraging results from early studies. These and other studies are prospectively investigating predictive clinical and molecular characteristics, with the ultimate goal of individualizing therapy in advanced NSCLC.
journal_name
Drugsjournal_title
Drugsauthors
Triano LR,Deshpande H,Gettinger SNdoi
10.2165/11532200-000000000-00000subject
Has Abstractpub_date
2010-01-01 00:00:00pages
167-79issue
2eissn
0012-6667issn
1179-1950pii
4journal_volume
70pub_type
杂志文章,评审相关文献
DRUGS文献大全abstract::Sacituzumab govitecan (sacituzumab govitecan-hziy; Trodelvy™) is a Trop-2-directed antibody conjugated to a topoisomerase I inhibitor (SN-38) that is being developed by Immunomedics for the treatment of solid tumours, including breast cancer. In April 2020, sacituzumab govitecan received accelerated approval in the US...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-020-01337-5
更新日期:2020-07-01 00:00:00
abstract::Torasemide (torsemide) is a high-ceiling loop diuretic which acts on the thick ascending limb of the loop of Henle to promote rapid and marked excretion of water, sodium and chloride. Like furosemide (frusemide), its major site of action is from the luminal side of the cell. Torasemide is at least twice as potent as f...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199141010-00008
更新日期:1991-01-01 00:00:00
abstract::Atherosclerosis can be defined in terms of the processes involved rather than in morphological terms, and there is evidence for possible roles of the macrophage in atherogenesis. The relevance of hyperlipidaemia to the morphogenesis of the atherosclerotic plaque is important, and this has been described in animal mode...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-198800363-00012
更新日期:1988-01-01 00:00:00
abstract::Allergic rhinitis represents a global health burden. The disease can seriously affect quality of life and is associated with multiple co-morbidities. Histamine and leukotrienes are important pro-inflammatory mediators in nasal allergic inflammation. Their actions on target cells are mediated through specific receptors...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200767180-00006
更新日期:2007-01-01 00:00:00
abstract::The continuous-use combination oral contraceptive ethinylestradiol/levonorgestrel 20microg/90microg suppresses gonadotropins, and subsequently ovulation and endometrial thickening, and suppresses breakthrough bleeding. Amenorrhoea and absence of breakthrough bleeding increase in incidence with extended administration....
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200767160-00010
更新日期:2007-01-01 00:00:00
abstract::Nadroparin calcium is a low molecular weight heparin with a mean molecular weight of 4.5 kD. Compared with unfractionated heparin, nadroparin calcium has a greater ratio of anti-factor Xa/anti-factor IIa activity. Nadroparin calcium has a longer half-life and greater bioavailability than unfractionated heparin and can...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199244050-00010
更新日期:1992-11-01 00:00:00
abstract::Management of renal cell carcinoma (RCC) has made considerable progress in recent years, and new emerging strategies are being developed. On the basis of the results of two randomised studies in the early 2000s, nephrectomy has now become the standard as cytoreductive surgery before embarking on systemic treatment wit...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200767090-00002
更新日期:2007-01-01 00:00:00
abstract::Cilazapril is an orally active angiotensin converting enzyme (ACE) inhibitor which lowers peripheral vascular resistance without affecting heart rate. Like enalapril and ramipril it is a prodrug, and is hydrolysed after absorption to cilazaprilat, which has a long terminal phase elimination half-life permitting once d...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199141050-00008
更新日期:1991-05-01 00:00:00
abstract::Avapritinib (AYVAKIT™) is a potent and selective tyrosine kinase inhibitor of platelet-derived growth factor receptor alpha (PDGFRA) and KIT activation loop mutants. It is being developed by Blueprint Medicines for the treatment of gastrointestinal stromal tumours (GIST), solid tumours and systemic mastocytosis. Avapr...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-020-01275-2
更新日期:2020-03-01 00:00:00
abstract::Aliskiren/hydrochlorothiazide is a single-pill combination of the first in the new class of non-peptide direct renin inhibitors (aliskiren) and a thiazide diuretic (hydrochlorothiazide [HCTZ]) that achieves blood pressure (BP) reductions greater than those seen with either component alone. In double-blind, 8-week clin...
journal_title:Drugs
pub_type: 杂志文章
doi:10.2165/00003495-200969070-00004
更新日期:2009-01-01 00:00:00
abstract::Increases in cancer diagnosis have tremendous negative impacts on patients and their families, and major societal and economic costs. The beneficial effect of chemotherapeutic agents on tumor suppression comes with major unwanted side effects such as weight and hair loss, nausea and vomiting, and neuropathic pain. Che...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-019-01132-x
更新日期:2019-06-01 00:00:00
abstract::This narrative review reports on the pharmacological and pharmacokinetic properties of rotigotine, a non-ergolinic D₃/D₂/D₁ dopamine receptor agonist approved for the treatment of early- and advanced-stage Parkinson's disease (PD) and moderate to severe restless legs syndrome (RLS). Rotigotine is formulated as a trans...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-015-0377-y
更新日期:2015-04-01 00:00:00
abstract::Orlistat is a nonsystemically acting gastric and pancreatic lipase inhibitor that limits the absorption of dietary fat. A retrospective pooled analysis of three 2-year, double-blind, randomised, placebo-controlled trials involving patients with obesity revealed that orlistat recipients were more likely to experience a...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200161140-00011
更新日期:2001-01-01 00:00:00
abstract::Airway inflammation is central to the pathophysiology of asthma, with treatment directed towards modification of this inflammation and its consequences. The relationship between cigarette smoking and airway inflammation is also well described, but relatively little data are available on the potential influence of smok...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200565110-00005
更新日期:2005-01-01 00:00:00
abstract::HIV-associated wasting, characterised by progressive loss of lean body mass and bodyweight, remains a significant problem in the era of highly active antiretroviral therapy (HAART). Loss of body cell mass, a component of lean body mass, is associated with decreased survival. Somatropin (recombinant human growth hormon...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200666030-00014
更新日期:2006-01-01 00:00:00
abstract::Glucocorticoids (GCs) are often used for improvement of quality of life, particularly in the elderly, but long-term GC use may cause harm; bone loss and fractures are among the most devastating side effects. Fracture risk is particularly high in patients with a severe underlying disease with an urgent need for treatme...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-019-01145-6
更新日期:2019-07-01 00:00:00
abstract::Lumasiran (Oxlumo™) is a subcutaneously administered small interfering RNA (siRNA) targeting the mRNA for hydroxyacid oxidase 1 gene (HAO1; encodes glycolate oxidase) and was developed by Alnylam Pharmaceuticals for the treatment of primary hyperoxaluria type 1 (PH1). By silencing the gene encoding glycolate oxidase, ...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-020-01463-0
更新日期:2021-01-06 00:00:00
abstract:UNLABELLED:Zolpidem is an imidazopyridine agent that is indicated for the short term (< or = 4 weeks) treatment of insomnia (recommended dosage 10 mg/day in adults and 5 or 10 mg/day in the elderly or patients with hepatic impairment). Data have shown that the hypnotic efficacy of zolpidem is generally comparable to th...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200059040-00014
更新日期:2000-04-01 00:00:00
abstract::Acyclovir (aciclovir) is a nucleoside antiviral drug with antiviral activity in vitro against members of the herpes group of DNA viruses. As an established treatment of herpes simplex infection, intravenous, oral and to a lesser extent topical formulations of acyclovir provide significant therapeutic benefit in genita...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-198937030-00002
更新日期:1989-03-01 00:00:00
abstract::Levocetirizine (Xyzal) is a selective, potent, oral histamine H(1) receptor antagonist of the latest generation that is licensed for the symptomatic treatment of allergic rhinitis (including persistent allergic rhinitis [PER]) and chronic idiopathic urticaria (CIU). Large, well designed trials indicate that levocetiri...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200666070-00017
更新日期:2006-01-01 00:00:00
abstract::Insulin degludec (Tresiba(®)) is an ultra-long-acting insulin analogue that is also available as a coformulation with rapid-acting insulin aspart (insulin degludec/insulin aspart) [Ryzodeg(®)]. Insulin degludec has a flat, stable glucose-lowering profile with a duration of action of >42 h, and less within-patient day-...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-013-0051-1
更新日期:2013-05-01 00:00:00
abstract::Delamanid (Deltyba(®)), a nitroimidazo-oxazole derivative, is a new anti-tuberculosis (TB) drug which exhibits potent in vitro and in vivo antitubercular activity against drug-susceptible and -resistant strains of Mycobacterium tuberculosis. It is approved in several countries, including Japan and those of the EU, for...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-014-0331-4
更新日期:2015-01-01 00:00:00
abstract:OBJECTIVE:The aim of this article is to review data on the efficacy and safety of montelukast in the treatment of children with asthma. METHODOLOGY:Available published literature, including published abstracts, is reviewed. RESULTS:In patients aged 6 to 14 years with asthma (n = 27), montelukast 5mg demonstrated a si...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200059001-00005
更新日期:2000-01-01 00:00:00
abstract::Because platelets are so important in thrombus formation, drugs which inhibit platelet function (the 'antiplatelet drugs') have considerable potential as antithrombotic agents. Among the antiplatelet drugs, only aspirin, sulphinpyrazone, dipyridamole, hydroxychloroquine, and clofibrate have had wide clinical trial. Th...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-197918060-00002
更新日期:1979-12-01 00:00:00
abstract::Letermovir (Prevymis™) is an orally or intravenously administered cytomegalovirus (CMV) DNA terminase complex inhibitor being developed by Merck & Co., Inc., under a global license from AiCuris Anti-infective Cures GmbH. Letermovir has been approved in Canada and the USA for the prophylaxis of CMV infection and diseas...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-017-0860-8
更新日期:2018-01-01 00:00:00
abstract::Second-generation histamine H1 receptor antagonists (antihistamines) have been developed to reduce or eliminate the sedation and anticholinergic adverse effects that occur with older H1 receptor antagonists. This article evaluates second-generation antihistamines, including acrivastine, astemizole, azelastine, cetiriz...
journal_title:Drugs
pub_type: 杂志文章,meta分析
doi:10.2165/00003495-199957010-00004
更新日期:1999-01-01 00:00:00
abstract::Significant progress has been made in the battle against transmission of HIV-1 from mother to infant. Antiretroviral regimens covering the later part of gestation, labour and the first few weeks of neonatal life have shown great efficacy in reducing such transmission. With the advent of combination antiretroviral ther...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200262150-00004
更新日期:2002-01-01 00:00:00
abstract::Levetiracetam (Keppra®, E Keppra®) is an established second-generation antiepileptic drug (AED). Worldwide, levetiracetam is most commonly approved as adjunctive treatment of partial onset seizures with or without secondary generalization; other approved indications include monotherapy treatment of partial onset seizu...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/11204490-000000000-00000
更新日期:2011-03-05 00:00:00
abstract::Anthracyclines are among the most active drugs for the treatment of advanced breast cancer. Epirubicin has been found to be as effective as doxorubicin at equimolar doses but significantly better tolerated, especially in terms of alopecia, leucopenia, and cardiac toxicity. The role of anthracycline-containing regimens...
journal_title:Drugs
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.2165/00003495-199300452-00007
更新日期:1993-01-01 00:00:00
abstract::Pegylation of interferon-alpha-2a is associated with improved sustained virological response rates in patients with chronic hepatitis C. Subsequently, combination therapy with peginterferon-alpha-2a (40kD) [Pegasys] and ribavirin (Copegus trade mark, Rebetol) was investigated to establish if the efficacy of peginterfe...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200363070-00008
更新日期:2003-01-01 00:00:00